Based on network pharmacology and molecular docking, to explore the mechanism of Wumei Pill in improving diarrhea-predominant irritable bowel syndrome (IBS-D). Methods The active ingredients and corresponding targets in Wumei Pills were retrieved and predicted through the Traditional Chinese Medicine System Pharmacology Platform (TCMSP database), and the IBS-D targets were screened in GeneCard, OMIM and other databases, and Venn diagrams, " Traditional Chinese medicine-active ingredient-target" action network and PPI network, and GO, KEGG analysis and molecular docking and visualization of related results. Results Wumei Pills had 129 active ingredients and 191 therapeutic targets in the treatment of IBS-D. PPI network analysis yielded 30 core targets, including HSP90AA1, JUN, RELA, MAPK1, AKT1, ESR1, IL6, FOS, MAPK8, NCOA1, etc. GO analysis revealed 2177 biological processes (BP), 169 molecular functions (MF), and 77 cellular components (CC). KEGG analysis indicated that IL-17 signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway and NF-κB signaling pathway played a key role in the treatment of IBS-D with Wumei Pill. Molecular docking showed that the core targets JUN, MAPK1 and FOS were relatively stable in combination with some active ingredients. Conclusion Wumei Pills may bind to HSP90AA1, JUN, RELA, MAPK1, AKT1, ESR1, IL6 and other proteins through the active ingredients quercetin, β-sitosterol and kaempferol. Furthermore, il-17, TNF, Toll-like receptors, NF-κB and other signaling pathways are regulated to reduce inflammatory response, regulate intestinal microbes, improve immunity, and treat IBS-D